肠系膜血管重建术后胃肠道出血的发生率与预测因素
单中心回顾性研究纳入2009至2019年因肠系膜缺血行开放或腔内肠系膜血管重建的205例患者,评估术后30天和60天临床显著胃肠道出血(CS-GIH)的发生率及预测因素。CS-GIH发生率为18%,相关因素包括住院期间肠切除、急性起病、心房颤动、首次启用抗血小板治疗及支架置入。
要点
- 肠系膜血管重建术后24%患者出现胃肠道出血,18%为临床显著出血,中位时间术后6.5天。
- 住院期间肠切除(OR 11.29)、急性起病(OR 5.42)、心房颤动(OR 3.01)、首次抗血小板治疗(OR 2.61)、支架置入(OR 2.31)与CS-GIH风险升高相关。
- CS-GIH导致2例死亡(1%),28例(14%)延长或转入重症监护,21例(10%)需红细胞输注。
核心结论
- 肠系膜血管重建术后胃肠道出血风险高,近20%患者发生CS-GIH,增加并发症和住院资源消耗。
- 特定患者群体CS-GIH风险高,术后管理路径应考虑这些危险因素以减少CS-GIH、改善结局。
研究设计与样本
- 单中心回顾性研究,连续纳入2009至2019年接受开放或腔内肠系膜血管重建的肠系膜缺血患者。
- 排除非闭塞性肠系膜缺血、术中或术后24小时内死亡、无术后随访者,最终纳入205例(女性139例,68%;平均年龄69.9岁,范围18-92岁)。
- 开放手术93例(45%),腔内治疗93例(45%),杂交19例(9%)。
- 临床表现:慢性肠系膜缺血128例(62%),慢加急性45例(22%),急性32例(16%)。
主要发现
- 50例(24%)出现胃肠道出血,44例(21%)在术后30天内发生,中位时间术后6.5天。
- CS-GIH发生于37例(18%),导致死亡2例(1%),延长重症监护或转入重症监护28例(14%),红细胞输注21例(10%),诊断/治疗性内镜/结肠镜18例(9%),再入院14例(7%)。
- 内镜/结肠镜诊断9例(溃疡5例,血管扩张2例,吻合口出血或结肠坏死各1例),治疗4例,发现1例弥漫性出血需手术干预。
- 与CS-GIH风险升高相关的因素:住院期间肠切除(OR 11.29,P < .001)、急性起病(OR 5.42,P < .001)、心房颤动(OR 3.01,P = .004)、首次启用抗血小板治疗(OR 2.61,P = .01)、支架置入(OR 2.31,P = .03)。
关键数值与推荐
- CS-GIH定义为需红细胞输注、再入院、升级至重症监护、长期停用抗凝或需内镜/结肠镜检查。
- 主要终点为术后30天和60天内CS-GIH的发生率及预测因素。
临床怎么用
- 术后管理路径应考虑住院期间肠切除、急性起病、心房颤动、首次抗血小板治疗及支架置入等危险因素,以减少CS-GIH并改善结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Postoperative gastrointestinal hemorrhage (GIH) following mesenteric revascularization when performed either openly (OR) or endovascularly (ER) has been clinically observed but not reported. The aim of the study is to assess the incidence and predictors of GIH in patients undergoing mesenteric revascularization. METHODS: This was a single-center retrospective review of consecutive patients treated with open or endovascular mesenteric revascularization from 2009 to 2019. Patients with nonocclusive mesenteric ischemia, intraoperative or perioperative death within 24 hours, or no postoperative follow-up were excluded. Primary endpoints were incidence and predictors of clinically significant GIH (CS-GIH) within 30 and 60 days postoperatively. CS-GIH was defined if patients required red blood cell transfusion, hospital readmission, escalation to intensive care, prolonged discontinuation of anticoagulation, or need for endoscopy/colonoscopy. RESULTS: A total of 260 patients presented with mesenteric ischemia and underwent OR/ER. Two hundred five patients met inclusion criteria (139 female [68%]; mean age of 69.9 years [range, 18-92 years]). Presentation was chronic mesenteric ischemia in 128 patients (62%), acute-on-chronic in 45 (22%) and acute in 32 (16%). Ninety-three patients (45%) underwent OR, 93 (45%) ER, and 19 (9%) hybrid. Fifty patients (24%) presented with GIH, 44 (21%) within 30 days of OR/ER, at a median time of 6.5 days postoperatively. CS-GIH occurred in 37 patients (18%), which led to death in two patients (1%), prolongation of intensive care unit course or transfer to intensive care unit in 28 patients (14%), red blood cell transfusion in 21 (10%), diagnostic/therapeutic endoscopy/colonoscopy in 18 (9%), and hospital readmission in 14 patients (7%). Endoscopy/colonoscopy was diagnostic in nine patients (ulcer in five patients, angioectasia in two, and anastomotic bleeding or colonic necrosis in one each), therapeutic in four, and identifying one patient with diffuse bleeding requiring operative intervention. Factors associated with increased risk of CS-GIH were bowel resection during index hospitalization (odds ratio [OR], 11.29; P < .001), acute presentation (OR, 5.42; P < .001), atrial fibrillation (OR, 3.01; P = .004), first-time initiation of antiplatelet therapy (OR, 2.61; P = .01), and treatment with stenting (OR, 2.31; P = .03). CONCLUSIONS: Patients undergoing mesenteric revascularization are at high risk for postoperative GIH, which increases morbidity and hospitalization resources in nearly 20% of patients. Specific patient groups are at high risk for CS-GI hemorrhage. Postoperative care pathways should consider these risk factors to reduce CS-GIH after mesenteric revascularization to improve outcomes.
引用
- Farazdaghi A, Rodrigues DVS, Cassianni C, et al. Incidence and predictors of gastrointestinal hemorrhage following mesenteric revascularization. J Vasc Surg. 2024. PMID: 39566833. doi:10.1016/j.jvs.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。